5-Amino-1MQ is often listed beside research peptides, but it is not a peptide. It is a small molecule, 5-amino-1-methylquinolinium, studied as an inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Preclinical research has examined it in adipose tissue, metabolism and ageing muscle models.
MOTS-c peptide research stands out because the peptide is encoded in mitochondrial DNA rather than the nuclear genome. Since it was first described in 2015, preclinical studies have examined it in metabolic regulation, skeletal muscle and cellular stress responses.
The glow peptide name comes from the skin and tissue research the blend is associated with, but the product is not a single molecule. It combines separate peptides, each with its own structure and research history, which makes documentation more important than it is for a single compound.
NAD+ is often searched for as “NAD peptide,” but nicotinamide adenine dinucleotide is not a peptide at all. It is a dinucleotide coenzyme found in every living cell, where it carries electrons through metabolic reactions and serves as a substrate for enzymes involved in DNA repair and cellular signalling. That distinction shapes how the compound should be described, tested and handled in a laboratory.
GHK Cu peptide research starts with a very small molecule doing something chemically important: the tripeptide Gly-His-Lys can bind copper. That copper complex, GHK-Cu, has been studied in extracellular-matrix biology, fibroblast activity, collagen and elastin signalling, wound models, and skin research. The evidence is broader than it is for many catalog peptides, but it still needs to be separated by model, route, and product.
CJC 1295 ipamorelin research brings two growth-hormone-axis pathways into the same laboratory preparation. One component is intended to model signalling through the growth hormone-releasing hormone receptor, while ipamorelin is a growth hormone secretagogue associated with the ghrelin receptor.
KPV peptide research is interesting because the molecule is only three amino acids long, yet preclinical studies have examined it in inflammatory signalling, intestinal models, epithelial biology, and antimicrobial research. KPV is a useful example of why peptide research cannot be judged by molecular size alone.
Tesamorelin is a synthetic growth hormone-releasing hormone analogue with a defined 44-amino-acid structure and a substantial research history. It acts through the GHRH receptor, influencing growth hormone and downstream IGF-1 signalling. That background is useful, but it does not remove the need to verify the research material itself.
Tirzepatide has become an important research compound because it combines activity at two incretin receptors in one synthetic peptide. For laboratories, however, the useful question is not only what tirzepatide does in published pharmaceutical research. It is also whether the research material being considered is clearly identified, documented, and matched to the specifications on the product page.
Retatrutide peptide research has attracted attention because the molecule is designed to activate three metabolic hormone receptors: GIP, GLP-1, and glucagon. That triple-receptor profile makes retatrutide scientifically distinct from single- or dual-receptor compounds. It is also important to separate the investigational molecule described in clinical trials from third-party research materials.
